12:00 AM
Sep 03, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Afinitor Disperz everolimus regulatory update

FDA approved Afinitor Disperz everolimus from Novartis to treat subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) in patients >=1 year of age who require therapeutic intervention but are not amenable to surgery. Afinitor Disperz dissolves more rapidly and is available in smaller dose increments than the adult formulation of everolimus. Novartis plans to launch Afinitor Dizperz in 4Q12....

Read the full 289 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >